New Key Statistics Module, Z-Score and F-Score
NAS:CARM Key Ratios
| Market Cap $ M | 58.16 |
| Enterprise Value $ M | 11.63 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 5.57 |
| Price/Sales | 3.92 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 15.00 |
| EPS (TTM) $ | -1.96 |
| Beneish M-Score | 0.93 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -0.14 |
| EV-to-EBITDA | -0.14 |
| PEG | -- |
| Shares Outstanding M | 41.54 |
| Net Margin (%) | -538.81 |
| Operating Margin % | -565.71 |
| Pre-tax Margin (%) | -539.53 |
| Quick Ratio | 4.64 |
| Current Ratio | 4.64 |
| ROA % (ttm) | -72.61 |
| ROE % (ttm) | -171.70 |
| ROIC % (ttm) | -496.38 |
| Dividend Yield % | -- |
| Altman Z-Score | -7.09 |
CARM Number of Guru Trades
CARM Volume of Guru Trades
Gurus Latest Trades with NAS:CARM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:CARM is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
CARISMA Therapeutics Inc Insider Transactions
No Available Data
News about NAS:CARM
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers